Back grey_arrow_rt.gif
 
Archived NATAP Articles from January 2003
 
null.gif
 
 
  1. Influence of Coinfection with Hepatitis C Virus on Morbidity and Mortality Due to Human Immunodeficiency Virus Infection in the Era of Highly Active Antiretroviral Therapy (1/31/03)

    2.  
  2. CDC Hepatitis C Coordinators Conference: brief selected highlights. Remember the Alamo. (1/30/03)

    3.  
  3. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings (1/27/03)

    4.  
  4. Brief Report: Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing - written by Sean Emery (1/27/03)

    5.  
  5. ALT & Biopsy Predict Outcome (1/27/03)

    6.  
  6. Fatty Liver Disease, ALT, & Overweight (1/27/03)

    7.  
  7. Delavirdine Generics Deal in Works (1/24/03)

    8.  
  8. Knowledge of Genotypic Resistance Mutations Among Providers of Care to Patients with Human Immunodeficiency Virus (1/24/03)

    9.  
  9. Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment (1/24/03)

    10.  
  10. Pharmacia Nears Deal to Sell Cheaper Version of AIDS Drug to Undeveloped Nations - By SCOTT HENSLEY Staff Reporter of THE WALL STREET JOURNAL (1/24/03)

    11.  
  11. Serum Retinol Levels and the Risk of Fracture (1/23/03)

    12.  
  12. Differentiating hyperlipidaemia associated with antiretroviral therapy (1/21/03)

    13.  
  13. GLAXOSMITHKLINE AND ONO TO COLLABORATE ON DEVELOPMENT AND COMMERCIALISATION OF ONO-4128, A NEW CCR5 ANTAGONIST FOR HIV (1/21/03)

    14.  
  14. Does HIV Accelerate HCV Progression? (1/21/03)

    15.  
  15. The burden of hepatitis C in the United States (1/21/03)

    16.  
  16. Estimating future hepatitis C morbidity, mortality, and costs in the United States (1/21/03)

    17.  
  17. Clinical & Cost Implications of Early Viral Response Treatment Management Algorithms & Adherence During PegInterferon and Ribavirin Therapy (1/21/03)

    18.  
  18. The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection (1/17/03)

    19.  
  19. Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy (1/17/03)

    20.  
  20. Interleukin-2 Increases CD4+ Lymphocyte Numbers but Does Not Enhance Responses to Immunization: Results of A5046s (1/17/03)

    21.  
  21. Tipranavir Phase III Studies and Compassionate Access Program (1/16/03)

    22.  
  22. Tenofovir Resistance in Treatment-Naïve: study 903 tenofovir vs d4T (1/14/03)

    23.  
  23. The Secret War on Condoms - By NICHOLAS D. KRISTOF, NY Times, Jan 10, 2003 (1/14/03)

    24.  
  24. Multiple Characteristics of HAART Affect Adherence Described (1/14/03)

    25.  
  25. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors - Ronit Ben-Romano a; Assaf Rudich d; Dora Torok d; Sharon Vanounou a; Klaris Riesenberg b; Francisc Schlaeffer b; Amira Klip d; Nava Bashan a,c (1/14/03)

    26.  
  26. ROCHE ANNOUNCES PRICE ON RIBAVIRIN (1/14/03)

    27.  
  27. Roche Dramatically Reduces Cost of Combination Therapy for Millions of Americans Chronically Infected with Hepatitis C - Press Release from Roche (1/14/03)

    28.  
  28. Hepatitis C treatment may cost N.J. millions - By Mark Fazlollah and Jennifer Lin Philadelpha Inquirer, Jan 12 2003 (1/14/03)

    29.  
  29. Most States Are Cutting Medicaid Benefits, Study Says - By THE ASSOCIATED PRESS (1/14/03)

    30.  
  30. Dosing Kaletra With Efavirenz (1/14/03)

    31.  
  31. Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients (1/10/03)

    32.  
  32. New HCV and HBV Drugs - PRNewswire (1/9/03)

    33.  
  33. Liver Transplantation in HIV (1/9/03)

    34.  
  34. Liver Transplantation Update for HIV & IVDUs (1/8/03)

    35.  
  35. Hepatology Highlights - Hepatology, January 2003, Volume 37, Number 1 Harvey J. Alter, Viral Hepatitis Editor - (1/8/03)

    36.  
  36. Is HCV Curable? - Reported by Jules Levin - (1/8/03)

    37.  
  37. Food Combo as Good as Cholesterol Drugs - By Daniel DeNoon Source: WebMD Medical News - (1/7/03)

    38.  
  38. Interactions between recreational drugs and antiretroviral agents - Antoniou T, Tseng AL. HIV Program/Inner City Health, St. Michael's Hospital, Toronto, Ontario, Canada. PDF FORMAT - (1/7/03)

    39.  
  39. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals - (1/7/03)

    40.  
  40. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors - (1/7/03)

    41.  
  41. Efficacy of Efavirenz in Different Racial Groups - (1/3/03)

    42.  
  42. CDC SMALLPOX FACT SHEET - (1/3/03)

    43.  
  43. HCV Protease Inhibitors: Vertex VX-950 clinical trial in 2003 - (1/3/03)

    44.  
  44. FDA Approves d4T Once Daily, Extended Release Formulation - (1/3/03)

    45.  
  45. Does HCV Replicate Outside The Liver and It's Significance? - (1/3/03)

    46.  
  46. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B - (1/3/03)

    47.  
  47. Hepatitis C Protease Inhibitors - (1/3/03)

    48.